IMMUNOLOGIX LABORATORIES

IMMUNOGENICITY

ADA and NAb expertise

- Expertise in preclinical and clinical ADA assay development, validation, and sample analysis
- We establish a robust signal to noise baseline for comprehensive 3-tiered testing (screen, confirm, titer) within each method
- Direct and bridging formats including ELISA and MSD® platforms
- Expertise in NAb assay development, validation, and sample analysis
- Competitive ligand binding and cell-based neutralizing antibody assay formats
- Dedicated cell lab for cell-based NAb assay needs
- Customized, science-first approach
  - We customize assessments to the needs of the client based on each specific drug development program
  - In-depth project intake with comprehensive scientific support from our Translational Sciences experts
  - Clinically relevant strategies employed with high-quality solutions
- Custom drug labeling and characterization services

Assay Formats

- Bridging assays
- Sulfo-Tag MSD®
- DIG ELISA
- Direct assay
- Competitive ligand binding NAb assays
- Cell-based NAb assays
- Cell-based immunogenicity assays

Matrices

- Aqueous humor
- CSF
- Plasma
- Serum
- Whole blood

Therapeutic Modalities

- Antibodies
- Fabs
- scFvs
- Bi/multi-specific antibodies
- Pegylated proteins
- IgMs
- Biosimilars (Humira®, Herceptin®, Enbrel®, Eylea®)
- Antibody drug conjugates
- Antibody oligo conjugates
- Fusion proteins
- Adnectin fusions
- Peptides
- Therapeutic enzymes
- ASOs
- AAVs
- Oncolytic viruses
- Transgene products
- Allogenic cell therapies
- Exosomes
- Virus like particles
- GLP-1, GIP, glucagon agonists

NEW IN 2024

Project sponsors have direct access for consultation at ILX scientific office hours

- Assay development challenges
- Bioanalytical & biomarker strategies
- Alignment with regulator expectations
- Direct regulatory engagement
- Overarching drug development perspective to support recommendations